The private equity firm that acquired Walgreens as part of a $10 billion deal plans to double the pharmacy chain’s profitability over the next several years, sources say https://t.co/nsuldm5FX0 ...

Core Insights - CVS Health plans to expand its retail footprint in 2026 after a period of contraction, intending to open 60 stores, including 20 small pharmacy-only locations, while closing a few dozen [2][3] Group 1: Expansion Plans - CVS Health aims to open 60 new stores this year, marking a significant shift from the previous four years where it closed 1,100 locations and opened only 200 [2] - The expansion is attributed to the company's successful strategy of shutting underperforming stores and renegotiating contracts with health insurers [3] Group 2: Market Context - The retail pharmacy sector has faced challenges, including Rite Aid's bankruptcy and Walgreens being acquired by private equity, as drugstores contend with reduced drug reimbursements from health insurers and competition from discount chains and online retailers [3] - CVS has acquired 63 former Rite Aid and Bartell Drugs stores and the prescription files of 626 pharmacies across 15 states, enhancing its market position [8] Group 3: Consumer Engagement - CVS is leveraging its first-party data, which includes 90 million addressable consumers, to pursue a retail media initiative aimed at enhancing consumer engagement in-store [8] - The average dwell time at CVS pharmacies is about three minutes, presenting an opportunity for brands to engage consumers effectively [9]

Core Insights - CVS Health is opening its first pharmacy-only location in Chicago as part of a plan to establish nearly 20 similar sites this year to enhance access to pharmacy care [1][5]. Group 1: New Pharmacy Locations - The new pharmacy-only location in Chicago is situated at 2628 West Pershing Road and aims to improve access to medications, immunizations, and other health services [1]. - Each pharmacy-only site will feature a full-service pharmacy with a selection of over-the-counter products, covering an average footprint of around 3,000 square feet [2]. - Additional pharmacy-only locations are planned for Houston, TX, Roxbury, MA, Detroit, MI, and Brooklyn, NY in 2026 [5]. Group 2: Community Engagement and Health Needs - CVS Health emphasizes the importance of one-on-one interactions between pharmacists and patients, with 80% of patients preferring face-to-face pharmacy care [5]. - The company has strategically realigned its retail footprint to better meet the diverse health needs of the communities it serves [3][4]. - CVS Health operates various pharmacy formats, including traditional stores, store-in-store pharmacies, and locations with MinuteClinics, to cater to different community health needs [4]. Group 3: Company Overview - As of December 31, 2025, CVS Health operates approximately 9,000 retail pharmacy locations and more than 1,000 walk-in and primary care medical clinics [7]. - The company serves around 87 million plan members through its pharmacy benefits manager and provides health insurance products to over 37 million people [7]. - CVS Health aims to connect individuals to better health through personalized, technology-driven services, enhancing access to quality care and improving health outcomes [7].

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [19] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [22] - Full-year 2025 adjusted EBITDA was $115 million, exceeding previous guidance [25] - The company increased its cash balance to $66 million, up from $36 million in Q3 2025 [22] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year [19] - Script volume grew 14% year-over-year, with vaccine script volumes up 3% [19][20] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% [19] Market Data and Key Metrics Changes - The company anticipates a revenue forecast of $1.4 billion to $1.42 billion for 2026, reflecting new pricing impacts from the IRA [26] - The long-term care pharmacy environment is evolving with ongoing consolidation and increasing operational complexity [13] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [8] - The company aims to offset anticipated EBITDA impacts from the IRA and maintain service levels during industry transitions [12][11] - The focus remains on supporting partners with reliable execution amid industry changes [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth momentum despite industry challenges, raising 2026 adjusted EBITDA guidance to $120 million-$124 million [17][26] - The demographic shift with the aging population is expected to create incremental tailwinds for the company [13] - Management is closely monitoring the operational complexities introduced by the IRA [11] Other Important Information - The company completed three acquisitions mid-year, contributing to reported revenue growth of 18% for the full year [6] - The company achieved a full-year return on equity of 27% [8] Q&A Session Summary Question: Can you help us understand the durable aspects of Q4 results? - Management indicated that the run rate for EBITDA is approximately $110 million, with variability in Q4 not projected to continue [32] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved profitability [34] Question: What progress has been made in balancing profit contributions between generics and branded drugs? - Management noted progress in aligning gross margin dollars with the high volume of generic prescriptions [36] Question: Is the gap between potential margin and realized margin still the same? - Management indicated that the gap has increased to approximately 90 basis points [37] Question: Can you discuss opportunities arising from competitors facing challenges? - Management acknowledged potential opportunities from competitors in distress, particularly in the context of ongoing bankruptcy processes [48] Question: Are you seeing efficiencies in labor costs? - Management stated that efficiencies are primarily due to scaling the existing platform rather than improvements in labor inflation [49] Question: How is the integration of recently acquired facilities progressing? - Management reported faster ramp-up and integration of recently acquired facilities, particularly in the Pacific Northwest [56] Question: What is the outlook for M&A opportunities given the current market conditions? - Management expressed a robust pipeline for M&A in 2026, while remaining disciplined in their approach [60]

Core Insights - The pharmacy industry is experiencing a significant shift in customer behavior, with an increase in same-day delivery and online prescription options impacting traditional pharmacy visits [1][2] - Walgreens, under new ownership by Sycamore Partners, is adjusting its store closure strategy, reducing the number of planned closures from 1,200 to under 100 by 2026 [3][4][6] - Major pharmacy chains, including Rite Aid and CVS, are also closing locations as part of broader strategies to streamline operations amid financial challenges [8] Company-Specific Developments - Walgreens plans to invest in its remaining stores while accelerating the closure of underperforming locations to better align with changing consumer preferences [5] - Rite Aid has closed all remaining stores due to Chapter 11 bankruptcy, transferring prescription files to competitors like CVS and Walgreens [8] - CVS has announced the closure of approximately 270 stores in 2025, following earlier closures of around 900 locations between 2022 and 2024 [8] Industry Trends - The overall number of pharmacy locations is declining, with significant closures affecting market coverage and availability in certain states [9] - The trend of major pharmacy closures is indicative of broader financial challenges within the industry, prompting companies to adapt their business models [8]

Indian pharmacy chain giant exposed customer data and internal systems https://t.co/aXC8SQGbM9 ...

Core Viewpoint - Guardian Pharmacy Services, Inc. will present at the Raymond James Institutional Investors Conference on March 2, 2023, at 1:40 p.m. Eastern Time, with a live audio webcast available [1] Company Information - Guardian Pharmacy Services is a publicly traded company listed on the NYSE under the ticker symbol GRDN [1] - A replay of the webcast will be accessible shortly after the event and will remain available for 90 days [1]

Core Viewpoint - CVS stock has risen 40% over the last 12 months, significantly outperforming major indexes and achieving returns comparable to Nvidia in percentage terms, despite being a pharmacy chain [1] Group 1: Stock Performance and Market Perception - CVS was previously viewed as a problem stock, with concerns about rising medical costs, structural issues, and the effectiveness of its healthcare model [1][2] - At its lowest point, CVS stock traded at a steep discount, reflecting market skepticism about the company's future [2] Group 2: Financial Results - For Q4, CVS reported revenue of $105.7 billion, an increase of 8.2% year over year, while full-year 2025 revenue surpassed $400 billion, marking a new record [3] - Adjusted earnings per share rose to $6.75 for the year, up from $5.42 in 2024, and operating cash flow exceeded $10 billion [3] Group 3: Segment Performance - Growth was observed across all major segments: insurance, pharmacy services, and retail pharmacy [3] - Aetna's results were mixed, with some trends improving while others remained problematic, reflecting the complexities of the healthcare landscape [4][5] - CVS's pharmacy middleman and health services arm showed steady performance, while retail pharmacy volumes surged nearly 20% in the quarter, indicating the company's scale may be advantageous [6] Group 4: Strategic Goals and Industry Context - Management aims to position CVS as "America's most trusted health care company," though the claim may be viewed skeptically given the adversarial nature of the U.S. healthcare system [7] - The company's turnaround suggests it is navigating the complexities of the healthcare environment more effectively, though the effectiveness of scale and vertical integration remains uncertain [8]

Core Insights - CVS Health reported a decline in fourth-quarter profit but exceeded Wall Street estimates, driven by strength in its pharmacy benefit unit and robust prescription volume at its retail pharmacies [1] Financial Performance - The company experienced a decrease in profit for the fourth quarter, yet managed to outperform analysts' expectations [1] - The performance was bolstered by the pharmacy benefit unit, indicating a strong demand for prescription services [1] Business Segments - The pharmacy benefit unit showed significant strength, contributing positively to the overall performance of CVS Health [1] - Retail pharmacies also reported strong prescription volume, which played a crucial role in the company's ability to beat estimates [1]

Core Viewpoint - Earth Science Tech, Inc. (ETST) is set to report its financial results for the three months ending December 31, 2025, on February 17, 2026, after market close [1] Company Overview - ETST is a diversified holding company focused on the health and wellness sector, operating through wholly-owned subsidiaries [3] - The company has a vertically integrated portfolio that includes licensed compounding pharmacies, telemedicine platforms, and targeted healthcare facilities [3] - Current operations include RxCompoundStore.com and Mister Meds, which provide sterile and non-sterile medications across a growing network of U.S. states [3] - Telemedicine platforms Peaks Curative and Doconsultation.com connect patients with healthcare providers for personalized care [3] Additional Business Segments - Beyond healthcare, ETST manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand for innovative kitchen products [4] - The company is committed to social responsibility through the Earth Science Foundation, a non-profit organization aimed at assisting patients with prescription costs [4]